Form 4: Eli Lilly Exec Exercises RSUs, Sells Shares for Tax

Eli Lilly & Co. EVP Jacob Van Naarden exercised restricted stock units and sold a portion of the resulting shares to cover tax liabilities.

Summary

• Jacob Van Naarden, Executive Vice President, President LLY Oncology & Head of Corporate Business Development at Eli Lilly & Co., exercised 4,108 Restricted Stock Units (RSUs).
• The RSU exercise resulted in the acquisition of 4,108 shares of Eli Lilly common stock at an exercise price of $0.
• Concurrently, 1,909.375 shares of common stock were disposed of at a price of $1,037.15 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Van Naarden directly owns 22,760.61 shares of common stock.
• Indirect beneficial ownership includes 4,342 shares through the Van Naarden Family Trust and 4,302 shares by his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction rather than a significant indicator of company performance or strategic shift.

Positives

• The exercise of Restricted Stock Units indicates a vesting event, which is a positive for the executive's compensation.
• The transaction was made pursuant to a Rule 10b5-1 plan, indicating pre-planned and routine compensation activity.

Negatives

• A portion of the acquired shares (1,909.375 shares) was sold to cover tax liabilities, reducing the direct beneficial ownership.

Industry Context

StockSavvy.ai notes that the exercise of Restricted Stock Units and subsequent sale for tax purposes is a common and routine event for executives in the pharmaceutical industry, reflecting standard compensation practices and vesting schedules. This type of transaction typically does not signal a change in the company's strategic direction or performance.

Comparison to Industry Standards

• This type of RSU vesting and tax-related sale is a standard practice across publicly traded companies, including major pharmaceutical firms like Pfizer, Merck, and Johnson & Johnson, where executive compensation packages often include equity components that vest over time.
• The transaction price of $1,037.15 per share for Eli Lilly reflects the company's current market valuation, which is robust compared to many peers, driven by strong performance in key therapeutic areas.

Related Party Transactions

• Indirect beneficial ownership through the Van Naarden Family Trust and by spouse are disclosed, which are common related party disclosures for insider holdings.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine executive compensation event. It reflects the executive's vested interest in the company's equity.

Key Dates

Keywords

Eli Lilly, LLY, Jacob Van Naarden, Insider Trading, Form 4, Restricted Stock Units, RSU, Stock Compensation, Tax Withholding, Executive Compensation, Rule 10b5-1